Stock RNAZ TRANSCODE THERAPEUTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Press Releases TransCode Therapeutics, Inc.

Equities

RNAZ

US89357L3033

Real-time Estimate Cboe BZX
Other stock markets
 20:53:42 13/05/2024 BST 		5-day change 1st Jan Change
0.587 USD -58.37% Intraday chart for TransCode Therapeutics, Inc. -21.64% -90.32%
04-22 Certain Warrants of TransCode Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 22-APR-2024. CI
04-22 Certain Stock Options of TransCode Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 22-APR-2024. CI

Press Releases

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
TransCode Therapeutics Open Letter to Shareholders
AQ
TransCode Therapeutics : Shareholder Meeting - Form 8-K
PU
TransCode Therapeutics Announces FDA Clearance To Initiate Phase 1/2 Clinical Trial with TTX-MC138 in Patients with Advanced Solid Tumors
AQ
TransCode Therapeutics Reports 2023 Results; Provides Business Update
AQ
TransCode Therapeutics Announces Appointment of Daniel Vlock, M.D., as Chief Medical Officer
AQ
TransCode Therapeutics and Akribion Genomics Report Progress Developing CRISPR-Derived Technology for Cancer Treatment
AQ
TransCode Therapeutics Reports Publication of United States Patent Application Covering TransCode’s RIG-I Agonist Immunotherapeutic
AQ
Nasdaq Determines TransCode Therapeutics Compliance with Minimum Stockholders’ Equity Requirement and Continued Listing on The Nasdaq Stock Market
AQ
TransCode Therapeutics and Debiopharm Announce Collaboration to Develop Targeted Nucleic Acid Therapeutics for Cancer
AQ
TransCode Therapeutics Announces Closing of $7.25 Million Public Offering
AQ
TransCode Therapeutics Announces Pricing of $7.25 Million Public Offering
AQ
TransCode Therapeutics Reports Further Restructuring to Reduce Expenses and Increased Focus on Planned Phase 1 Clinical Trial, Retirement of CEO
AQ
TransCode Therapeutics Announces 1-for-40 Reverse Stock Split
AQ
TransCode Therapeutics Publishes Open Letter Outlining Company’s Progress and Objectives
AQ
TransCode Therapeutics Reports Positive Pre-Clinical Results in Metastatic Pancreatic Cancer with its Lead Candidate, TTX-MC138
AQ
TransCode Therapeutics To Present Phase 0 Data at 2023 San Antonio Breast Cancer Symposium
AQ
TransCode Therapeutics Announces Closing of $1.2 Million Registered Direct Offering of Common Stock Priced At-The-Market under Nasdaq Rules
AQ
TransCode Therapeutics Announces $1.2 Million Registered Direct Offering of Common Stock Priced At-The-Market under Nasdaq Rules
AQ
TransCode Therapeutics Reports Third Quarter 2023 Results; Provides Business Update
AQ
TransCode Therapeutics Withdraws Public Offering
AQ
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. RNAZ Stock
  4. News TransCode Therapeutics, Inc.
  5. Press Releases